Castle Biosciences Q3 2026 Earnings Call - CASTLE BIOSCIENCES INC

Explicit Guidance:

• FY2026 Total Revenue: Raised to $385–$395 million (midpoint increase of $20 million from prior range of $365–$375 million; $45 million increase from year-start guidance).
• FY2026 TissueCipher Volume: Reiterated full-year growth guidance of 50%–52% year-over-year compared to 2025.
• FY2026 DecisionDX Melanoma Volume: Revised outlook to mid-single-digit year-over-year growth (downgraded from previous expectations implied by "exceeding 10,000" run rates).
• Adjusted EBITDA: Expects positive adjusted EBITDA for Q4 2026, Full Year 2026, and Full Year 2027 (assuming no change in strategic direction).
• Q4 2026 Outlook: No explicit numerical range provided, but implied to be "strong" and "contingent on Q3 trends," with management acknowledging typical Q4 seasonality (holidays, fewer operating days) leading to a potentially flat or slightly down sequential revenue trajectory.

Business-Segment Outlook:

• TissueCipher (Barrett's Esophagus): Expected to maintain momentum through end of 2026; currently ~15% penetration rate among eligible surveillance endoscopy procedures with "plenty of room to go." Management anticipates continued growth in 2027 driven by penetration expansion, though seasonality (weather, holidays) and sales force transitions may cause quarterly variability.
• DecisionDX Melanoma: Remains the "central priority" for dermatology commercial organization; Q4 expected to be strong with year-to-date growth aligning with guidance. No structural changes or competitive pressures identified to derail volume targets.
• Advanced ADTX (Atopic Dermatitis): Volumes expected to open up in 2027–2028; currently paused on major commercial marketing push pending resolution of CMS pricing methodology (gap fill vs. crosswalk) and finalized ASPs.
• DecisionDX SEC: No revenue recovery assumptions included in 2027 plan; anticipated recovery timeline shifted to 2028. Expectation of a draft Local Coverage Determination (LCD) emerging in the "next couple of months" or early 2027, potentially following a Coverage Advisory Committee (CAC) meeting.
• ESOPredict/SR-PROTECT: Positioned as a clinical pivot product for TissueCipher cases with inadequate tissue; not a primary revenue driver but supports patient care continuity.

Market and Competitive Outlook:

• Payer Negotiations & ASPs: Expectation of steady ASPs for 2027 as a baseline model, with hopes for upside from commercial payer wins demonstrating clinical utility (risk-stratification for Barrett's esophagus) and economic benefits (reducing unnecessary procedures). No specific ASP growth modeled for 2027.
• Market Penetration: TissueCipher market remains under-penetrated (~15%); growth engine driven by adoption among existing clinician base and gradual addition of new ordering physicians.
• Commercial Focus: 2027 resource allocation heavily weighted toward DecisionDX Melanoma (dermatology) and TissueCipher (GI); ADTX marketing force paused pending policy clarity.
• Moderna Vaccine Impact: Potential long-term structural driver for DecisionDX Melanoma; anticipates that if adjuvant vaccines move into earlier-stage populations (1–2A), the test becomes more critical for selecting patients for early immunotherapy initiation.

Macro / Industry Outlook:

• Regulatory (CMS): CMS proposed "gap fill" pricing for Advanced ADTX despite advisory panel recommendations for "crosswalk." Final recommendation anticipated around Thanksgiving 2026 to early December 2026.
• Sales Force Dynamics: Recent sales force expansions on TissueCipher (completed Q2) are entering a fully operational phase; new managers/cases typically take 5–6 months to ramp. Management anticipates full impact of these additions to materialize in Q4 2026 and more significantly in 2027.
• Operational Seasonality: Acknowledges recurring seasonality in Q4 (December holidays, fewer operating days) and variable business days affecting reporting; no specific strategy to manage this, treating it as a structural business reality.

Strategic Initiatives:

• Pipeline Updates: Expect updates on pipeline progress and Sybase collaboration during H1 2027; no specific data or metrics planned for release prior to that.
• Capacity & Operations: Lab headcount (Pittsburgh and Scottsdale) expected to grow in tandem with test volume growth to maintain bandwidth, leveraging technology for incremental efficiencies.
• Commercial Alignment: Incentive structures and commercial focus realigned specifically to reinforce DecisionDX Melanoma as the primary dermatology priority.
• Clinical Evidence: Continued investment in clinical evidence generation (e.g., recent Annals of Gastroenterology study) to support payer and physician adoption of risk-aligned management decisions.

Risks and Headwinds to Outlook:

• Payer Policy Uncertainty: Final CMS pricing decision for Advanced ADTX (gap fill vs. crosswalk) and timing of coverage decisions for DecisionDX SEC remain key variables impacting 2027–2028 revenue assumptions.
• Revenue Mix & ASP Volatility: While ASPs have been strong, management notes "one-time pricing items" can influence trends; future ASP growth is not guaranteed and is modeled conservatively as flat.
• Sales Force Dislocation: Recent sales force restructuring may create temporary "bumpiness" in coverage and execution before stabilization.
• Execution Risk: Future performance relies on successful penetration of TissueCipher (15% current) and potential volume recovery for DecisionDX SEC, neither of which is assumed for 2027 revenue.
• External Factors: Weather events and holiday schedules (December) are cited as drivers of Q4 operational variability.

Management Tone on the Future:

• Confidence Level: High regarding core business momentum ("very successful," "strong growth," "durable foundation").
• Hedges: Explicitly states "no obligations to update" forward-looking statements; guidance for 2027 EBITDA is conditional ("absent a change in strategic direction"); 2028 revenue assumed for SEC recovery.
• Sentiment: Optimistic on long-term value creation and clinical utility, but pragmatic on regulatory timelines and seasonality; emphasizes "operational excellence" and "disciplined expense management."

Miscellaneous:

• Cash Position: Ended Q3 2026 with $278 million in cash, cash equivalents, and marketable investment securities; strong balance sheet supports growth priorities.
• Headcount Expansion: Lab headcount and G&A increased due to volume growth and wage adjustments; sales headcount maintained at ~100 for both core businesses, deemed sufficient for now.
• Non-GAAP: Adjusted EBITDA for Q3 2026 was $12.7 million; Gross Margin held at 75% (Adjusted 77%); Net Loss was $4.1 million.